Neuropeptide S Reinstates Cocaine-seeking Behavior and Increases Locomotor Activity Through Corticotropin-releasing Factor Receptor 1 in Mice

Overview

Journal J Neurosci

Specialty Neurology

Date 2009 Apr 3

PMID 19339610

Citations 43

Authors

Covadonga Paneda

Salvador Huitron-Resendiz

Laura M Frago

Julie A Chowen

Roberto Picetti

Luis De Lecea

Amanda J Roberts

Affiliations

Soon will be listed here.

Abstract

Neuropeptide S (NPS) is a recently discovered neuropeptide that increases arousal and wakefulness while decreasing anxiety-like behavior. Here, we used a self-administration paradigm to demonstrate that intracerebroventricular infusion of NPS reinstates extinguished cocaine-seeking behavior in a dose-dependent manner in mice. The highest dose of NPS (0.45 nM) increased active lever pressing in the absence of cocaine to levels that were equivalent to those observed during self-administration. In addition, we examined the role of the corticotropin-releasing factor receptor 1 (CRF(1)) in this behavior as well as locomotor stimulation and anxiolysis. CRF(1) knock-out mice did not respond to either the locomotor stimulant or cocaine reinstatement effects of NPS, but still responded to its anxiolytic effect. The CRF(1) antagonist antalarmin also blocked the increase in active lever responding in the reinstatement model and the locomotor activating properties of NPS without affecting its anxiolytic actions. Our results suggest that NPS receptors may be an important target for drug abuse research and treatment and that CRF(1) mediates the cocaine-seeking and locomotor stimulant effects of NPS, but not its effects on anxiety-like behavior.

Citing Articles

A cluster of neuropeptide S neurons regulates breathing and arousal.

Angelakos C, Girven K, Liu Y, Gonzalez O, Murphy K, Jennings K Curr Biol. 2023; 33(24):5439-5455.e7.

PMID: 38056461 PMC: 10842921. DOI: 10.1016/j.cub.2023.11.018.

Peroxisome proliferator-activated receptor-α activation facilitates contextual fear extinction and modulates intrinsic excitability of dentate gyrus neurons.

Xiang G, Liu X, Wang J, Lu S, Yu M, Zhang Y Transl Psychiatry. 2023; 13(1):206.

PMID: 37322045 PMC: 10272150. DOI: 10.1038/s41398-023-02496-1.

Effect of Kisspeptin-Type Neuropeptide on Locomotor Behavior and Muscle Physiology in the Sea Cucumber .

Guo X, Zhang L, Xiao K Animals (Basel). 2023; 13(4).

PMID: 36830492 PMC: 9951865. DOI: 10.3390/ani13040705.

A Role for Neuropeptide S in Alcohol and Cocaine Seeking.

Cannella N, Borruto A, Petrella M, Micioni Di Bonaventura M, Soverchia L, Cifani C Pharmaceuticals (Basel). 2022; 15(7).

PMID: 35890099 PMC: 9317571. DOI: 10.3390/ph15070800.

Identification of a Novel Neuropeptide S Receptor Antagonist Scaffold Based on the SHA-68 Core.

Zarkin A, Jahan R, Uprety R, Zhang Y, McElhinny C, Snyder R Pharmaceuticals (Basel). 2021; 14(10).

PMID: 34681248 PMC: 8538004. DOI: 10.3390/ph14101024.

References

Xu Y, Reinscheid R, Huitron-Resendiz S, Clark S, Wang Z, Lin S . Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron. 2004; 43(4):487-97. DOI: 10.1016/j.neuron.2004.08.005. View

Jungling K, Seidenbecher T, Sosulina L, Lesting J, Sangha S, Clark S . Neuropeptide S-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in the amygdala. Neuron. 2008; 59(2):298-310. PMC: 2610688. DOI: 10.1016/j.neuron.2008.07.002. View

Reinscheid R, Xu Y . Neuropeptide S and its receptor: a newly deorphanized G protein-coupled receptor system. Neuroscientist. 2005; 11(6):532-8. DOI: 10.1177/1073858405276405. View

Boutrel B, Kenny P, Specio S, Martin-Fardon R, Markou A, Koob G . Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci U S A. 2005; 102(52):19168-73. PMC: 1323172. DOI: 10.1073/pnas.0507480102. View

Reinscheid R, Xu Y, Civelli O . Neuropeptide S: a new player in the modulation of arousal and anxiety. Mol Interv. 2005; 5(1):42-6. DOI: 10.1124/mi5.1.8. View

Specio S, Wee S, ODell L, Boutrel B, Zorrilla E, Koob G . CRF(1) receptor antagonists attenuate escalated cocaine self-administration in rats. Psychopharmacology (Berl). 2007; 196(3):473-82. PMC: 2769571. DOI: 10.1007/s00213-007-0983-9. View

Bruijnzeel A, Gold M . The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence. Brain Res Brain Res Rev. 2005; 49(3):505-28. DOI: 10.1016/j.brainresrev.2005.01.007. View

Roberts A, Polis I, GOLD L . Intravenous self-administration of heroin, cocaine, and the combination in Balb/c mice. Eur J Pharmacol. 1997; 326(2-3):119-25. DOI: 10.1016/s0014-2999(97)85405-2. View

Rivier C, Vale W . Cocaine stimulates adrenocorticotropin (ACTH) secretion through a corticotropin-releasing factor (CRF)-mediated mechanism. Brain Res. 1987; 422(2):403-6. DOI: 10.1016/0006-8993(87)90953-x. View

10.

Smith G, Aubry J, Dellu F, Contarino A, Bilezikjian L, GOLD L . Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron. 1998; 20(6):1093-102. DOI: 10.1016/s0896-6273(00)80491-2. View

11.

Koob G, Le Moal M . Drug abuse: hedonic homeostatic dysregulation. Science. 1997; 278(5335):52-8. DOI: 10.1126/science.278.5335.52. View

12.

Shaham Y, Erb S, Leung S, Buczek Y, Stewart J . CP-154,526, a selective, non-peptide antagonist of the corticotropin-releasing factor1 receptor attenuates stress-induced relapse to drug seeking in cocaine- and heroin-trained rats. Psychopharmacology (Berl). 1998; 137(2):184-90. DOI: 10.1007/s002130050608. View

13.

Njunge K, Handley S . Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav. 1991; 38(1):63-7. DOI: 10.1016/0091-3057(91)90590-x. View

14.

Lowry C, Moore F . Regulation of behavioral responses by corticotropin-releasing factor. Gen Comp Endocrinol. 2006; 146(1):19-27. DOI: 10.1016/j.ygcen.2005.12.006. View

15.

Jaffe J, Cascella N, Kumor K, Sherer M . Cocaine-induced cocaine craving. Psychopharmacology (Berl). 1989; 97(1):59-64. DOI: 10.1007/BF00443414. View

16.

Leonard S, Dwyer J, Sukoff Rizzo S, Platt B, Logue S, Neal S . Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology (Berl). 2008; 197(4):601-11. DOI: 10.1007/s00213-008-1080-4. View

17.

Thomsen M, Caine S . Intravenous drug self-administration in mice: practical considerations. Behav Genet. 2007; 37(1):101-18. DOI: 10.1007/s10519-006-9097-0. View

18.

Shaham Y, Shalev U, Lu L, de Wit H, Stewart J . The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl). 2002; 168(1-2):3-20. DOI: 10.1007/s00213-002-1224-x. View

19.

Xu Y, Gall C, Jackson V, Civelli O, Reinscheid R . Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the rat brain. J Comp Neurol. 2006; 500(1):84-102. DOI: 10.1002/cne.21159. View

20.

Steckler T, Dautzenberg F . Corticotropin-releasing factor receptor antagonists in affective disorders and drug dependence-- an update. CNS Neurol Disord Drug Targets. 2006; 5(2):147-65. DOI: 10.2174/187152706776359619. View